Bruker Corporation has announced the Beacon Discovery™ Optofluidic System, a game-changing benchtop platform designed to make live single-cell functional analysis more accessible and affordable for laboratories of all sizes. Debuting at AACR 2025, Beacon Discovery leverages Bruker's industry-leading technologies to deliver high-quality, customizable workflows with intuitive operation.
For lab managers balancing tight budgets and growing scientific demands, Beacon Discovery offers an opportunity to expand capabilities in immuno-oncology, infectious disease research, and regenerative medicine. It bridges functional analysis and downstream genomic studies, enabling deep biological insights from the same single cells.
With its lower cost of ownership and streamlined user interface, Beacon Discovery supports flexible, high-impact research without the complexity of traditional platforms.
How Beacon Discovery benefits lab managers:
- Significantly reduces cost barriers for advanced single-cell analysis
- Intuitive workflows minimize training time and increase user adoption
- Modular and scalable design fits diverse research needs
- Enables multi-day, multi-parameter experiments with minimal supervision
- Facilitates cross-team collaboration by linking functional assays with genomic profiling
- Backed by Bruker's Technology Access Program (TAP) for early user experience
Pre-orders are now available, and shipments are expected to begin later in 2025, offering labs a timely path to next-generation single-cell research.
This article has been sourced from a press release and may include content created or refined using AI tools and verified by our editorial team. The original press release was provided by Bruker.
